PRODUCTS
SERVICES
COMPANY
CONTACT
FAQ
Search
Dictionary
Mobile
Login
Login/Nickname:
Password:
Remember login
Login
Send password reminder...
Dianne Tomita Selected Research
Anemia
06/2008
Treating Anemia of Cancer with Every-4-Week Darbepoetin Alfa: Final Efficacy and Safety Results from a Phase II, Randomized, Double-Blind, Placebo-Controlled Study.
10/2007
A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia.
06/2007
Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: a controlled, randomized, open-label phase II trial.
05/2007
The effectiveness of darbepoetin alfa administered every 3 weeks on hematologic outcomes and quality of life in older patients with chemotherapy-induced anemia.
05/2006
Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial.
04/2006
Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia.
12/2005
Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly.
01/2004
A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.
11/2003
A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia.
07/2003
Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks.
10/2002
Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis.
Articles by Research Topic
Disease
11
Anemia
06/2008 - 10/2002
4
Neoplasms (Cancer)
06/2008 - 07/2003
1
Breast Neoplasms (Breast Cancer)
12/2005
1
Fatigue
07/2003
1
Lung Neoplasms (Lung Cancer)
08/2002
Drug/Important Bio-Agent (IBA)
12
darbepoetin alfa (Aranesp)
FDA Link
06/2008 - 08/2002
4
Epoetin Alfa (Epogen)
FDA Link
05/2006 - 11/2003
Therapy/Procedure
10
Drug Therapy (Chemotherapy)
10/2007 - 08/2002